Table 1.

Patient clinical information

Patient no.Age (y)SexDisease statusDisease stage at original diagnosisHDI completedResponse
Duration of disease-free interval (mo)Current status
ClinicalPathologic
80150MIT4aN2b(cl)1/3DRCRRMiD32Deceased
80342MIT4bNxYesNRRMaD6Deceased
80465FRT3aN0(s)YesNRRMaD1Deceased
80541MRT1bN0(cl)YesPRRMiD49NED
80656MRT3a(al)N0(cl)YesNRCR34MET
80766FRT3bN0(s)YesNRRMaD32NED
80956FIT4bN3(cl)YesNRRMaD6Deceased
81060MIT4bN2b(cl)YesNRRMaD6Deceased
81172FRT3aN0(cl)YesPRRMaD30NED
81276MRTxN0(s)YesPRRMaD15MET
81457FITxN3(cl)1/3DRPRRMaD4Deceased
81762MIPTxN3(cl)1/3DRPRRMaD10NED
  • NOTE: Adapted from ref. 18.

    Abbreviations: M, male; F, female; I, initial presentation; R, regional lymph node recurrence; IP, isolated palpable nodal metastases arising from an unknown primary; cl, nodal staging based on clinical exam; s, nodal staging based on sentinel lymph node mapping and pathologic interpretation; DR, dose reduction; CR, complete response; PR, partial response; NR, no response; RMiD, residual microscopic disease; RMaD, residual macroscopic disease; NED, no evidence of disease; MET, metastatic disease.